AI drug hunter Exscientia chops down 'rapidly emerging pipeline' to focus on 2 main oncology programs

AI drug discovery technology can churn out a lot of promising candidates, but, at some point, the reality of the biotech world hits all companies: Only the best of the best should be advanced. Exscientia is paring back its “rapidly emerging pipeline” to focus on the highest value possibilities.